NK cells propagate T cell immunity following in situ tumor vaccination
Summary: We report an in situ vaccination, adaptable to nearly any type of cancer, that combines radiotherapy targeting one tumor and intratumoral injection of this site with tumor-specific antibody and interleukin-2 (IL-2; 3xTx). In a phase I clinical trial, administration of 3xTx (with an immunocy...
| 出版年: | Cell Reports |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Elsevier
2023-12-01
|
| 主題: | |
| オンライン・アクセス: | http://www.sciencedirect.com/science/article/pii/S2211124723015681 |
